This HTML5 document contains 26 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/domain/vavai/cep/kategorie/
n10http://linked.opendata.cz/resource/domain/vavai/cep/soutez/
dctermshttp://purl.org/dc/terms/
n2http://linked.opendata.cz/resource/domain/vavai/cep/projekt/MSM/
n11http://linked.opendata.cz/resource/domain/vavai/cep/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/cep/obor/
n8http://linked.opendata.cz/resource/domain/vavai/cep/druh-souteze/
n6http://linked.opendata.cz/resource/domain/vavai/cep/smlouva/1081/
n12http://linked.opendata.cz/resource/domain/vavai/cep/faze/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/domain/vavai/cep/typ/
n7http://linked.opendata.cz/resource/domain/vavai/cep/poskytovatel/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:OC10042
rdf:type
n4:Projekt
dcterms:description
Na základě našich předběžných výsledků a údajů z literatury chceme získat nové informace o epigenetické regulaci leukemogeneze AML a progrese MDS a tím přispět k individualizaci a zvýšení účinnosti léčby AML a MDS. (max.255 znaků) Hematological malignancies, such as other malignancies, have specific epigenetic alterations of tumor suppressor genes, genes involved in differentiation, apoptosis, metastasis etc. The alterations of gene promoter methylation lead to uncontrolled proliferation of leukemic cells and malignant transformation. The DNA methylation changes can be used to detect leukemic cells in peripheral blood. We will examine the DNA methylation status of a wide spectrum of genes by the use of DNA methylation PCR arrays which allows us to observe multiple changes in gene methylation profile. These arrays are convenient for a more detail insight of epigenetic modifications occurring during the malignant transformation of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). We will choose the panel of the most promising genes based on our previous results from cultivation with demethylating agents such as Decitabine and on recently published data from genome-wide methylation studies. We will assess the
dcterms:title
Application of DNA methylation arrays for assessment of aberrantly methylated genes in MDS and AML patients Studium aberantně metylovaných genů u pacientů s MDS a AML pomocí DNA metylačních arrayí.
n4:cislo-smlouvy
n6:2011-320
n4:dalsi-vedlejsi-obor
n5:EB
n4:druh-souteze
n8:VS
n4:faze
n12:54687970
n4:hlavni-obor
n5:FD
n4:vedlejsi-obor
n5:FP
n4:id-aktivity
n11:OC
n4:id-souteze
n10:SMSM2010OC5
n4:kategorie
n13:1
n4:klicova-slova
hypermethylation; tumor suppressor genes; epigenetics; minimal residual disease; demethylation drugs; DNA methylation array; MDS; AML
n4:konec-reseni
2012-11-30+01:00
n4:pocet-koordinujicich-prijemcu
0
n4:poskytovatel
n7:MSM
n4:start-reseni
2010-05-01+01:00
n4:statni-podpora
2100
n4:typProjektu
n9:P
n4:uznane-naklady
2400
n4:pocet-prijemcu
1
n4:pocet-spoluprijemcu
0
n4:pocet-vysledku
1
n4:pocet-vysledku-zverejnovanych
1